<script src="https://cdn.tailwindcss.com"></script>
<script>
  tailwind.config = {
    content: [
      './templates/**/*.html.twig',
      './js/**/*.js',
    ],
    theme: {
      extend: {
        colors: {
          primary: {
            DEFAULT: '#a05ea6',
            light: '#a05ea6',
            10: 'rgba(160, 94, 166, 0.1)',
            gradient: {
              start: '#A05EA7',
              end: '#765FA4'
            }
          },
          secondary: '#739549',
          text: {
            DEFAULT: '#191919',
            muted: '#777776'
          },
          border: {
            muted: 'rgba(115, 117, 120, 0.3)'
          },
          teal: '#0080a3',
          dark: '#231f20'
        },
        fontFamily: {
          sans: ['Arial', 'sans-serif'],
        },
        container: {
          center: true,
          padding: '1rem',
          screens: {
            sm: '640px',
            md: '768px',
            lg: '1024px',
            xl: '1280px',
            '2xl': '1440px',
          },
        },
        spacing: {
          '18': '4.5rem',
        },
        backgroundImage: {
          'fade-white': 'linear-gradient(to bottom, #fff 80%, rgba(255,255,255,0) 100%)',
          'primary-gradient': 'linear-gradient(to right, #A05EA7, #765FA4)',
          'teal-primary-gradient': 'linear-gradient(to right, #0081a3 0%, #a05fa6 322.36%)',
          'teal-primary-gradient-2': 'linear-gradient(to right, #0081a3 -110.9%, #a05fa6 211.89%)',
          'teal-primary-gradient-3': 'linear-gradient(to right, #0081a3 -221.37%, #a05fa6 100%)'
        }
      },
    },
    plugins: [],
  }
</script>

  <div class="w-[375px] h-[1397.75px]">
  <div class="flex flex-col items-center w-[375px] top-[734px] gap-6 px-3 pb-12">
    <p class="w-[351px] text-center text-text">
      <span class="text-[32px] font-semibold">CHOLBAM may help your patients with SLOS</span>
      <span class="text-[40px]">1-3*:</span>
    </p>
    <div class="flex flex-col items-start w-full">
      <div class="flex flex-col items-center w-full gap-2 pt-2 pb-6 rounded-2xl">
        <div class="px-24 gap-2.5"></div>
        <div class="flex flex-col items-center gap-8">
          <div class="flex flex-col items-center gap-4">
            <p class="w-[351px] text-[26px] text-center text-teal">
              <span class="font-semibold">Increase plasma cholesterol</span><span>†</span>
            </p>
          </div>
        </div>
      </div>
      <div class="flex flex-col items-center w-full gap-2 pt-2 pb-6 rounded-2xl">
        <div class="px-24 gap-2.5"></div>
        <div class="flex flex-col items-center gap-8">
          <div class="flex flex-col items-center gap-4">
            <p class="w-[351px] text-[26px] font-semibold text-center text-teal">
              Lower key liver enzymes
            </p>
            <div class="flex flex-col items-center gap-4">
              <p class="w-[351px] text-lg text-left text-text">
                <span>Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values </span>
                <span class="font-bold">reduced</span>
                <span> to less than 50 U/L, or baseline levels </span>
                <span class="font-bold">reduced</span>
                <span> by 80%. </span><br><br>
                <span>Total bilirubin values </span>
                <span class="font-bold">reduced</span>
                <span> to less than or equal to 1 mg/dL.</span>
              </p>
            </div>
          </div>
        </div>
      </div>
      <div class="flex flex-col items-center w-full gap-2 pt-2 rounded-2xl">
        <div class="px-24 gap-2.5"></div>
        <div class="flex flex-col items-center gap-8">
          <div class="flex flex-col items-center gap-4">
            <p class="w-[351px] text-[26px] font-semibold text-center text-teal">
              Improve certain growth parameters
            </p>
            <div class="flex flex-col items-center gap-4">
              <p class="w-[351px] text-lg text-left text-text">
                <span>In a pivotal study, responders saw a </span>
                <span class="font-bold">10% increase in body weight or maintained weight above the 50th percentile</span>
                <span>.1*</span><br><br>
                <span>In a 2-month pilot study, 9 of 12 patients showed an </span>
                <span class="font-bold">increasing trend in weight gain</span>
                <span> from baseline, though statistical significance was not reached.2 </span>
              </p>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="w-[375px] h-[1895px]">
  <div class="flex flex-col items-start w-[375px] top-[687px] overflow-hidden pt-[47px] bg-white">
    <div>
      <div>
        <div class="bg-[url('frame-626231.png')]">
          <div class="flex flex-col items-center w-[375px] gap-10 px-3 pb-12">
            <div class="w-full gap-2">
              <p class="w-[351px] text-[32px] font-semibold text-center text-text">
                Years of Clinical Data and Real-World Use
              </p>
              <p class="w-[351px] text-lg text-left text-text">
                Backed by &gt;18 years of safety data, CHOLBAM has a well-characterized safety and
                tolerability profile. There were 12 adverse reactions reported across 9 patients in
                the clinical trials.1‡ In clinical trials, the most common adverse reaction (~2%)
                reported was diarrhea.1
              </p>
            </div>
            <div class="flex flex-col justify-center items-center h-[248px] w-[375px] relative">
              <div class="flex flex-col justify-center items-center h-[352px] w-[375px] absolute left-0 top-[-52px] pt-8 pb-14">
                <p class="w-[375px] text-[26px] font-semibold text-center text-white">
                  CHOLBAM has been FDA approved and helping patients absorb what matters since 2015.
                </p>
              </div>
            </div>
            <div class="flex flex-col items-start w-full gap-4">
              
              <!-- Footnotes section -->
              <div class="flex flex-col items-start w-full">
                <div class="w-full">
                  <div class="flex items-start w-full relative">
                    <p class="w-[351px] text-sm text-left text-text">
                      No evaluable patients with SLOS were in the pivotal studies.1 Patients had
                      other bile acid synthesis disorders due to single enzyme defects.
                    </p>
                    <p class="text-sm text-left text-text">*</p>
                  </div>
                  <div class="flex items-start w-full relative gap-2">
                    <p class="w-[351px] text-sm text-left text-text">
                      In 11 of 12 patients with SLOS given CHOLBAM 10 mg/kg/day and cholesterol
                      supplementation for 2 months, in an open-label, pilot study. Long-term studies
                      are needed to determine durability of effect and possible clinical benefits.2
                    </p>
                    <p class="text-sm text-left text-text">†</p>
                  </div>
                </div>
                <div class="flex items-start w-full relative">
                  <p class="w-[351px] text-sm text-left text-text">
                    <span>Clinical safety experience with CHOLBAM consists of1:</span><br>
                    <span>Trial 1: a non-randomized, open-label, single-arm trial of 50 patients with
                      bile acid synthesis disorders due to single enzyme defects (SEDs) and 29
                      patients with peroxisomal disorders (PDs) including Zellweger spectrum
                      disorders. Safety data are available over the 18 years of the trial</span><br>
                    <span>Trial 2: an extension trial of 12 new patients (10 SED and 2 PD) along with
                      31 (21 SED and 10 PD) patients who rolled over from Trial 1</span><br>
                    <span>Safety data are available for 3 years and 11 months of treatment. Adverse
                      events were not collected systematically in either of these trials. Most
                      patients received an oral dose of 10 to 15 mg/kg/day of CHOLBAM.</span>
                  </p>
                  <p class="text-sm text-left text-text">‡</p>
                </div>
                <div class="flex items-start w-full relative gap-2">
                  <p class="text-sm text-left text-text">
                    Adverse reactions that occurred in new patients.
                  </p>
                  <p class="text-sm text-left text-text">§</p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>